目的 綜合評價胰膽管合流異常（PBM）與膽囊癌發生的關系，為膽囊癌的預防提供更多、更準確的信息。 方法 計算機檢索中國生物醫學文獻數據庫（CBM）、中國期刊網（CNKI）、PubMed、EMBASE、萬方等數據庫，檢索時間從1977年4月－2011年5月，并結合文獻追溯的方法，收集國內外公開發表的關于PBM與膽囊癌關系的病例對照研究或隊列研究，采用RevMan 5.0.25軟件進行Meta分析。 結果 總計納入文獻8篇，其中3篇僅對比分析了PBM在膽囊癌患者與正常對照組中發生率的差異，2篇僅對比分析了膽囊癌在PBM患者與正常對照組中發生率的差異，而另外3篇文獻則對這兩種發生率的差異都進行了對比。Meta分析結果顯示：膽囊癌患者中PBM的發生率明顯高于正常對照組，差異有統計學意義[OR=7.41，95%CI（5.03，10.87），P＜0.000 01]；且PBM患者中膽囊癌的發生率明顯高于正常對照組，差異有統計學意義[OR=17.67，95%CI（10.43，29.94），P＜0.000 01]。 結論 PBM是膽囊癌發生的高危因素，與膽囊癌的發生密切相關。
Objective To assess the effectiveness and safety of prulifloxacin in the treatment of urinary tract infection. Methods The double-blind, double dummy and randomized controlled method was adopted. One hundred and forty-four patients were randomized to the treatment group (prulifloxacin , 4 tablets, bid) and the control group (levofloxacin, 4 tablets, bid). The randomization code was produced by computer. The treatment duration for both groups was from 7 to 10 days. Results Data were analyzed on the basis of full analysis sets (FAS) and per-protocol (PP) analysis. The total improvement rates of the trial and control groups were 85.07% and 88.52% respectively by FAS analysis, and 90.48% and 91.53% respectively by PP analysis. There was no significant difference between the two groups in improvement rates (Pgt;0.05). Bacterial negative rates in the trial and control groups were 93.75% and 93.88% respectively by FAS analysis and 97.83% and 97.87% respectively by PP analysis. The results showed no statistical significance difference between the two groups in bacterial negative rates (Pgt;0.05). The adverse events in the prulifloxacin and levofloxacin groups were 2.80% and 5.60% respectively. Conclusion Prulifloxacin has the same clinical effectiveness as levofloxacin with a few toxic adverse effects in the treatment of urinary tract infection.